Antimetastatic Activities of Modified Heparins: Selectin Inhibition by Heparin Attenuates Metastasis

ABSTRACT

Heparin, which is traditionally used as an anticoagulant but has a variety of additional biological activities, was shown in several retrospective and prospective clinical trials to have an effect on cancer survival. Experimental evidence from animal models consistently demonstrates that heparin is an efficient inhibitor of metastasis. To clarify the mechanism of heparin antimetastatic activity, several biological effects are being investigated. Cancer progression and metastasis are associated with enhanced expression of heparanase, which is inhibited efficiently by heparin. Heparin is also a potent inhibitor of selectin-mediated interactions. P- and L-selectin were shown to contribute to the early stages of metastasis, which is associated with platelet-tumor cell thrombi formation. To delineate the biological activities of heparin contributing to metastasis inhibition, modified heparins with specific activities were evaluated. Low anticoagulant heparin preparations still inhibited metastasis efficiently, indicating that anticoagulation is not a necessary component for heparin attenuation of metastasis. Modified heparins characterized for heparanase inhibitory activity are also potential inhibitors of selectins. Selectin inhibition is a clear component of heparin inhibition of metastasis. The contribution of selectin or heparanase inhibition by heparin can provide evidence about its antimetastatic activity.

KEYWORDS

Heparin - metastasis - selectin - heparanase - anticoagulation

REFERENCES

• 1 Zacharski L R, Ornstein D L, Mamourian A C. Low-molecular-weight heparin and cancer.  Semin Thromb Hemost. 2000;  26(suppl 1) 69-77
• 2 Lee A Y, Levine M N, Baker R I et al.. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.  N Engl J Med. 2003;  349 146-153
• 3 Lee A Y, Rickles F R, Julian J A et al.. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.  J Clin Oncol. 2005;  23 2123-2129
• 4 Kakkar A K, Levine M N, Kadziola Z et al.. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).  J Clin Oncol. 2004;  22 1944-1948
• 5 Altinbas M, Coskun H S, Er O et al.. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer.  J Thromb Haemost. 2004;  2 1266-1271
• 6 Klerk C P, Smorenburg S M, Otten H M et al.. The effect of low molecular weight heparin on survival in patients with advanced malignancy.  J Clin Oncol. 2005;  23 2130-2135
• 7 Smorenburg S M, Van Noorden C J. The complex effects of heparins on cancer progression and metastasis in experimental studies.  Pharmacol Rev. 2001;  53 93-105
• 8 Zacharski L R, Ornstein D L. Heparin and cancer.  Thromb Haemost. 1998;  80 10-23
• 9 Niers T M, Klerk C P, Dinisio M et al.. Mechanisms of heparin induced cancer activity in experimental cancer models.  Crit Rev Oncol Hematol. 2007;  61 195-207
• 10 Lee A E, Rogers L A, Longcroft J M, Jeffery R E. Reduction of metastasis in a murine mammary tumour model by heparin and polyinosinic-polycytidylic acid.  Clin Exp Metastasis. 1990;  8 165-171
• 11 Vlodavsky I, Mohsen M, Lider O et al.. Inhibition of tumor metastasis by heparanase inhibiting species of heparin.  Invasion Metastasis. 1994;  14 290-302
• 12 Poggi A, Rossi C, Casella N et al.. Inhibition of B16-BL6 melanoma lung colonies by semisynthetic sulfaminoheparosan sulfates from E. coli K5 polysaccharide.  Semin Thromb Hemost. 2002;  28 383-392
• 13 Amirkhosravi A, Mousa S A, Amaya M, Francis J L. Antimetastatic effect of tinzaparin, a low-molecular-weight heparin.  J Thromb Haemost. 2003;  1 1972-1976
• 14 Ludwig R J, Boehme B, Podda M et al.. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis.  Cancer Res. 2004;  64 2743-2750
• 15 Borsig L, Wong R, Feramisco J et al.. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis.  Proc Natl Acad Sci USA. 2001;  98 3352-3357
• 16 Borsig L, Wong R, Hynes R O, Varki N M, Varki A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis.  Proc Natl Acad Sci USA. 2002;  99 2193-2198
• 17 Stevenson J L, Choi S H, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins-correlation with selectin inhibition, not antithrombotic activity.  Clin Cancer Res. 2005;  11 7003-7011
• 18 Ludwig R J, Alban S, Bistrian R et al.. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo.  Thromb Haemost. 2006;  95 535-540
• 19 Lindahl U. ‘Heparin'-from anticoagulant drug into the new biology.  Glycoconj J. 2000;  17 597-605
• 20 Lever R, Page C P. Novel drug development opportunities for heparin.  Nat Rev Drug Discov. 2002;  1 140-148
• 21 Nelson R M, Cecconi O, Roberts W G et al.. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation.  Blood. 1993;  82 3253-3258
• 22 Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents.  J Clin Invest. 1998;  101 877-889
• 23 Wang L, Brown J R, Varki A, Esko J D. Heparin's inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins.  J Clin Invest. 2002;  110 127-136
• 24 Wei M, Gao Y, Tian M, Li N, Hao S, Zeng X. Selectively desulfated heparin inhibits P-selectin-mediated adhesion of human melanoma cells.  Cancer Lett. 2005;  229 123-126
• 25 Parish C R, Freeman C, Brown K J, Francis D J, Cowden W B. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity.  Cancer Res. 1999;  59 3433-3441
• 26 Edovitsky E, Elkin M, Zcharia E, Peretz T, Vlodavsky I. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis.  J Natl Cancer Inst. 2004;  96 1219-1230
• 27 Cohen I, Pappo O, Elkin M et al.. Heparanase promotes growth, angiogenesis and survival of primary breast tumors.  Int J Cancer. 2006;  118 1609-1617
• 28 Vlodavsky I, Abboud-Jarrous G, Elkin M et al.. The impact of heparanase and heparin on cancer metastasis and angiogenesis.  Pathophysiol Haemost Thromb. 2006;  35 116-127
• 29 Kansas G S. Selectins and their ligands: current concepts and controversies.  Blood. 1996;  88 3259-3287
• 30 Borsig L. Selectins facilitate carcinoma metastasis and heparin can prevent them.  News Physiol Sci. 2004;  19 16-21
• 31 Kim Y J, Varki A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer.  Glycoconj J. 1997;  14 569-576
• 32 Nakamori S, Kameyama M, Imaoka S et al.. Involvement of carbohydrate antigen sialyl Lewis(x) in colorectal cancer metastasis.  Dis Colon Rectum. 1997;  40 420-431
• 33 Jorgensen T, Berner A, Kaalhus O, Tveter K J, Danielsen H E, Bryne M. Up-regulation of the oligosaccharide sialyl LewisX: a new prognostic parameter in metastatic prostate cancer.  Cancer Res. 1995;  55 1817-1819
• 34 Yamaguchi A, Ding K, Maehara M, Goi T, Nakagawara G. Expression of nm23-H1 gene and Sialyl Lewis X antigen in breast cancer.  Oncology. 1998;  55 357-362
• 35 Renkonen J, Paavonen T, Renkonen R. Endothelial and epithelial expression of sialyl Lewis(x) and sialyl Lewis(a) in lesions of breast carcinoma.  Int J Cancer. 1997;  74 296-300
• 36 Laubli H, Stevenson J L, Varki A, Varki N M, Borsig L. L-selectin facilitation of metastasis involves temporal induction of fut7-dependent ligands at sites of tumor cell arrest.  Cancer Res. 2006;  66 1536-1542
• 37 Wei M, Tai G, Gao Y et al.. Modified heparin inhibit P-selectin-mediated cell adhesion of human colon carcinoma cells to immobilized platelets under dynamic flow conditions.  J Biol Chem. 2004;  279 29202-29210
• 38 Karpatkin S, Pearlstein E, Ambrogio C, Coller B S. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo.  J Clin Invest. 1988;  81 1012-1019
• 39 Nieswandt B, Hafner M, Echtenacher B, Mannel D N. Lysis of tumor cells by natural killer cells in mice is impeded by platelets.  Cancer Res. 1999;  59 1295-1300
• 40 Sciumbata T, Caretto P, Pirovano P et al.. Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival.  Invasion Metastasis. 1996;  16 132-143
• 41 Fuster M M, Brown J R, Wang L, Esko J D. A disaccharide precursor of sialyl Lewis X inhibits metastatic potential of tumor cells.  Cancer Res. 2003;  63 2775-2781
• 42 Lapierre F, Holme K, Lam L et al.. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, tumor and metastatic properties.  Glycobiology. 1996;  6 355-366
• 43 Ono K, Ishihara M, Ishikawa K et al.. Periodate-treated, non-anticoagulant heparin-carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung.  Br J Cancer. 2002;  86 1803-1812
• 44 Yoshitomi Y, Nakanishi H, Kusano Y et al.. Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity.  Cancer Lett. 2004;  207 165-174
• 45 Kragh M, Binderup L, Vig Hjamaa P J et al.. Non-anti-coagulant heparin inhibits metastasis but not primary tumor growth.  Oncol Rep. 2005;  14 99-104
• 46 Naggi A, Casu B, Perez M et al.. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting.  J Biol Chem. 2005;  280 12103-12113
• 47 Varki N M, Varki A. Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans.  Semin Thromb Hemost. 2002;  28 53-66